SCHEMBL4256141

SCHEMBL4256141

COC(=O)c1cccc(S(=O)(=O)C(C)C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 2/20 0.52
KMT2A Q03164 1/20 0.52
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA9 Q16790 1/20 0.51
LOX P28300 1/20 0.50
TCF4 P15884 2/20 0.49
CTNNB1 P35222 2/20 0.49
SLC40A1 Q9NP59 1/20 0.48
LOXL2 Q9Y4K0 1/20 0.47
ACLY P53396 2/20 0.47
TSHR P16473 1/20 0.47
CTSG P08311 1/20 0.47
CMA1 P23946 1/20 0.47
GAA P10253 1/20 0.47
PKM P14618 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2884607 0.83 LOX (0.66) POLBALDH1A1KDM4EKMT2ACA12
SCHEMBL2651155 0.81 POLB (0.61) POLBALDH1A1KDM4EKMT2ACA12
SCHEMBL1100084 0.81 ALDH1A1 (0.59) POLBALDH1A1KDM4EKMT2ACA12
SCHEMBL3293304 0.81 POLB (0.57) POLBALDH1A1KDM4EKMT2ACA12
SCHEMBL9008002 0.81 ALDH1A1 (0.59) POLBALDH1A1KDM4EKMT2ACA12
SCHEMBL17689604 0.81 ALDH1A1 (0.53) POLBALDH1A1KMT2ACA12CA1
SCHEMBL4248336 0.81 F2 (0.53) ALDH1A1KDM4EKMT2ACA1CA2
SCHEMBL29971360 0.81 F2 (0.53) ALDH1A1KDM4EKMT2ACA1CA2
SCHEMBL17048482 0.80 LOX (0.50) POLBALDH1A1KDM4EKMT2ACA12
SCHEMBL119413 0.80 POLB (0.55) POLBALDH1A1KDM4EKMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12383560-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-08-12 US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-11497752-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2022-11-15 US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 US disclosed
CN-112153984-A Compound and use thereof 福宏治疗公司 2020-12-29 CN disclosed
EP-3746124-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2020-12-09 EP disclosed
US-10682419-B2 Prodrugs of peptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2020-06-16 US disclosed
US-20160263234-A1 PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS ONYX THERAPEUTICS, INC. 2016-09-15 US disclosed
US-9315542-B2 Prodrugs of peptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2016-04-19 US disclosed
US-9309283-B2 Prodrugs of peptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2016-04-12 US disclosed
US-20140105921-A1 Prodrugs of Peptide Epoxy Ketone Protease Inhibitors ONYX THERAPEUTICS, INC. 2014-04-17 US disclosed
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors FLECK ROMAN WOLFGANG 2009-09-10 US disclosed
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors FLECK ROMAN WOLFGANG 2009-09-10 US disclosed
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors FLECK ROMAN WOLFGANG 2009-09-10 US disclosed
EP-1960367-A2 SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2008-08-27 EP disclosed
WO-2007067836-A2 SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-14 WO disclosed
WO-2007067836-A2 SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140105921-A1 Prodrugs of Peptide Epoxy Ketone Protease Inhibitors PREP, VIP, PEPD POLB 4109/4885ALDH1A1 1285/4885KDM4E 377/4885
US-20160263234-A1 PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS PREP, VIP, PEPD POLB 4109/4885ALDH1A1 1285/4885KDM4E 377/4885
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB POLB 165/4885ALDH1A1 2571/4885KDM4E 1848/4885
US-12383560-B2 Compounds and uses thereof VHL, CLN6, TFEB POLB 165/4885ALDH1A1 2571/4885KDM4E 1848/4885
US-10682419-B2 Prodrugs of peptide epoxy ketone protease inhibitors PREP, VIP, PEPD POLB 4109/4885ALDH1A1 1285/4885KDM4E 377/4885
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors EPHX1, EPHX2, EPX POLB 1495/4885ALDH1A1 376/4885KDM4E 1988/4885
US-11497752-B2 Compounds and uses thereof VHL, CLN6, TFEB POLB 165/4885ALDH1A1 2571/4885KDM4E 1848/4885
US-20210038611-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB POLB 165/4885ALDH1A1 2571/4885KDM4E 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.